الفهرس | Only 14 pages are availabe for public view |
Abstract MCS continues to be one of the most dynamic therapies in medicine and, as reported in this essay, is being studied extensively across the globe to ensure optimal outcomes. Durable devices are under the most intense investigation with a shift in focus from survival to a reduction in adverse events and minimizing negative patient –device interactions. At the forefront of this will be a further study into the growing problem of LVAD thrombosis, which was highlighted in a special edition of the Journal of Heart and Lung Transplantation and a high-profile study by leading U S. centers.(182) Factors studied as part of this process will include patient, device, and practice variables but will also require careful assessment of current and future regulatory oversight in MCS therapy |